Precision Medicine in Oncology®

Checkpoint Inhibitors in Small-Cell Lung Cancer

Frontline Immunotherapy Combinations for NSCLC

Checkpoint Inhibitor Biomarkers for Lung Cancer

Emerging Landscape of Immunotherapy in NSCLC

Latest Videos

Q & A Session for Hematologic Malignancies

MRD Testing in Hematologic Malignancies

$Phase III Data for Relapsed/Refractory Myeloma$

Phase III Data for Relapsed/Refractory Myeloma

Key Studies in Newly-Diagnosed Multiple Myeloma

Daratumumab for Smoldering Myeloma

KRd for High-Risk Smoldering Myeloma

AML Studies: BiTE Antibodies and Age for Transplant

AML Studies: FLT3 Inhibitors

Acute Myeloid Leukemia: Novel Targeted Therapies

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

CME Content

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Empire State Hematology and Oncology Society

Jack W. Erter III, MD, MMHC; Geoffrey Ku, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Frantz Francisque, MD; Jacob Sands, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Komal Jhaveri, MD, FACP; Ruta D. Rao, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Kentucky Society of Clinical Oncology

Sunnie S. Kim, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | South Carolina Oncology Society

Geoffrey Ku, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Texas Society of Clinical Oncology

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Tennessee Oncology Practice Society

1 Session is Available!

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Texas Society of Clinical Oncology

1 Session is Available!

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Daniela A. Bota, MD, PhD; Maya Hrachova, DO

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Amy E. Armstrong, MD; Anu Batra, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Daniela A. Bota, MD, PhD; Shiven Patel, MD, MBA

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Jack W. Erter III, MD, MMHC; Anne Chiang, MD, PhD

Washington State Medical Oncology Society

1 Session is Available!

In-Person + Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

December 4, 2026

Wyoming State Oncology Society

1 Session is Available!

Montana State Oncology Society

1 Session is Available!

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

In-Person + Virtual Event

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Washington State Medical Oncology Society

Mrinal M. Gounder, MD; Megan Jagosky, MD

Breast Cancer Symposia in San Antonio

December 7, 2026

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Iowa Oncology Society

Ravin Ratan, MD, M.Ed; Megan Jagosky, MD

Empire State Hematology & Oncology Society (New York)

2 Sessions are Available!

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

South Carolina Oncology Society

2 Sessions are Available!

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Wisconsin Association of Hematology and Oncology

Neel Belani, MD; Eric K. Singhi, MD

In-Person + Virtual Event

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Neil M. Iyengar, MD; Ajit K. Bisen, MD, MBA

Annual Hematology Meeting Preceding the 68th ASH Annual Meeting and Exposition

December 11, 2026

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Nevada Oncology Society

Mrinal M. Gounder, MD; Makenzi Evangelist, MD

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Northern California

Yana G. Najjar, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Erika P. Hamilton, MD; Katherine Sanchez, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | West Virginia Oncology Society

Priya Kumar, MBBS, MS; Christine L. Hann, MD, PhD

Nevada Oncology Society

1 Session is Available!

Louisiana Oncology Society

1 Session is Available!

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD

Missouri Oncology Society

1 Session is Available!

Cases and Conversations: Implementing Recent Updates to Improve Outcomes for Patients With MDS

December 18, 2026

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Jonathan Riess, MD, MS; Fawzi Abu Rous, MD; Julia Rotow, MD

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

(CPE Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD; Jonathan Strosberg, MD